Skip to main content
U.S. flag

An official website of the United States government

LATE 2022

On this page:


February 11, 2022 from 1:00 p.m. to 6:00 p.m., ET

Purpose and background

LATE, short for Limbic-predominant Age-related TDP-43 Encephalopathy, is a brain disorder that is related to the slow progression of memory loss in aging, thereby mimicking the clinical features of Alzheimer’ disease. Like Alzheimer’s disease, LATE is very common in older persons and has a large public health impact. Unlike Alzheimer’s disease, there is little recognition and research on LATE. This sparked a workshop on LATE in 2018 and the inclusion of a session on LATE at the subsequent Alzheimer’s Disease-Related Dementias Summit in 2019. These initiatives increased awareness and accelerated research on LATE, but there is an urgent need for more research to uncover the clinical impacts and biological causes of the disease.

LATE 2022 was an open follow-up meeting organized in collaboration with NIA to continue the conversation on LATE with a series of talks and discussions on the research since the 2018 workshop. The meeting included a wide range of topics including epidemiology, clinical and imaging features, potential biomarkers, and genetic studies in LATE. The meeting also highlighted the important intersection between LATE and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP), including similarities as well as important differences that distinguish the two, and the common co-occurrence of LATE with Alzheimer’s disease. The goals of LATE 2022 were to provide updates, stimulate discussion, and consider future directions. All are invited to attend.

Meeting recording

Watch a recording of the LATE 2022 meeting.


Pre-recorded short presentations related to LATE are available on the NACC YouTube channel.

February 11, 2022

1:00pm-2:30pm, ET: Session 1 | LATE: Evolving Concepts and Clinical Relevance

  • 1:00pm-2:30pm, ET: Talks
    • Introduction, Dr. Julie Schneider, Rush University
    • Clinical perspectives on LATE, Dr. Ron Petersen, Mayo Clinic
    • The impact of LATE in AD prevention clinical trials: Challenges and Opportunities, Dr. Reisa Sperling, Harvard University
    • Impact of LATE on cognitive trajectories, Dr. Patricia Boyle, Rush University
    • LATE-NC and ALS/FTLD-TDP: Neuropathological criteria, boundary issues, and open questions, Dr. Manuela Neumann, University of Tubingen
    • LATE: Where we were, where we are, and where we're going, Dr. Pete Nelson, University of Kentucky
  • 2:30pm-3:00pm: Discussion
    • Discussion leaders: Dr. Dennis Dickson, Mayo Clinic and Dr. Dirk Keene, University of Washington

3:00pm-3:30pm, ET: Break

3:30pm-5:30pm, ET: Session 2 | Lightning round presentations and discussion on pathology, genetics, epidemiology, and biomarkers

  • 3:30-4:00pm, ET: Pathology
    • LATE-NC in the Adult Changes in Thought study, Dr. Caitlin Latimer, University of Washington
    • “Early LATE”: Patterns and associations of TDP-43 pathology in the amygdala region, Dr. Matt Cykowski, Houston Methodist Hospital
    • Synaptic changes in the setting of co-existing TDP43 and Alzheimer’s disease neuropathologic change, Dr. Margaret Flanagan, Northwestern University
    • Variable effect of LATE-NC on cognitive decline in the FLAME series, Dr. Melissa Murray, Mayo Clinic
    • Discussion leader: Dr. Lea Grinberg, University of California San Francisco
  • 4:00-4:30pm, ET: Genetics
    • Candidate genes for limbic-predominant age-related TDP-43 encephalopathy, Dr. Dave Fardo, University of Kentucky
    • Shared and distinct genetic risk factors of LATE-NC, Dr. Hyun-Sik Yang, Harvard University
    • LATE genetics: Interactions and outliers, Dr. Eddie Lee, University of Pennsylvania
    • Discussion leader: Dr. Phil de Jager, Columbia University

4:30-4:45pm ET: Break

  • 4:45-5:15pm, ET: Epidemiology
    • TDP-43, GVD and dementia: The Cambridge City over-75s Cohort (CC75C), Dr. Sally Hunter, Cambridge University
    • LATE-NC and multiple proteinopathy in a community-based cohort of brain aging: Results from University of Kentucky Alzheimer’s Disease Research Center, Dr. Erin Abner, University of Kentucky
    • LATE-NC and dementia in the oldest-old: Findings from The 90+ study, Dr. Maria Corrada, University of California Irvine
    • Discussion leader: Dr. Carol Brayne, Cambridge University
  • 5:15pm-5:45pm, ET: Biomarkers
    • Unique contribution of TDP-43 to antemortem hippocampal shape morphometry, Dr. Lei Wang, The Ohio State University
    • High throughput plasma bioassays for LATE, Dr. Robert Rissman, University of California San Diego
    • In-vivo stratification of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC, Dr. Michel Grothe, Instituto de Biomedicina de Sevilla and DZNE, German Center for Neurodegenerative Diseases
    • Discussion leader: Dr. Konstantinos Arfanakis, Rush University/Illinois Institute of Technology
  • 5:45pm, ET: Brief concluding remarks

Contact information

Please contact Dr. Nina Silverberg and Grayson Donley for questions you may have about this workshop.

Additional information

Reasonable Accommodation: If you need reasonable accommodation to participate in this event, please contact the meeting organizer listed under Contact Information. Please make your request no later than 1 week before the event.

An official website of the National Institutes of Health